Today: 11 April 2026
Subscribe
Browse Category

NASDAQ:TERN 16 December 2025 - 26 March 2026

Terns Pharmaceuticals (TERN) Stock Holds Near Merck’s $53 Offer After $6.7 Billion Buyout

Terns Pharmaceuticals (TERN) Stock Holds Near Merck’s $53 Offer After $6.7 Billion Buyout

Terns Pharmaceuticals shares traded at $52.86 in U.S. premarket Thursday, just below Merck’s $53-per-share cash offer after Merck agreed to acquire the company for about $6.7 billion. The deal centers on Terns’ leukemia drug TERN-701, which showed a 75% major molecular response rate in early trials. The offer requires over 50% of shares tendered and antitrust approval. Terns would owe Merck $235 million if it accepts a higher bid.
26 March 2026
···
Merck to Buy Terns Pharmaceuticals for $6.7 Billion to Boost Cancer Pipeline as Keytruda Patent Expiry Nears

Merck to Buy Terns Pharmaceuticals for $6.7 Billion to Boost Cancer Pipeline as Keytruda Patent Expiry Nears

Merck will acquire Terns Pharmaceuticals for $53 per share in cash, valuing the company at about $6.7 billion. The deal gives Merck rights to TERN-701, an experimental leukemia drug, as it prepares for Keytruda’s patent expirations in 2028. The offer represents a 6% premium to Terns’ last close and is subject to antitrust review and shareholder approval. Merck expects to close the transaction in the second quarter.
25 March 2026
··
Structure Therapeutics stock jumps as Novo deal talk lifts obesity-drug names

Structure Therapeutics stock jumps as Novo deal talk lifts obesity-drug names

Structure Therapeutics (GPCR) shares surged 7.5% to $83.76 Wednesday on over 1 million shares traded, fueled by buyout speculation and renewed interest in oral obesity drugs. Novo Nordisk executives signaled openness to acquisitions, while Structure reported Phase 2b data showing its oral GLP-1 drug aleniglipron led to 11.3% placebo-adjusted weight loss at 36 weeks. Viking Therapeutics and Terns Pharmaceuticals also rose sharply.
14 January 2026
······
Terns Pharmaceuticals (TERN) Stock Today (Dec. 18, 2025): Why Shares Are Sliding After the Rally, and What Analysts Forecast Next

Terns Pharmaceuticals (TERN) Stock Today (Dec. 18, 2025): Why Shares Are Sliding After the Rally, and What Analysts Forecast Next

Terns Pharmaceuticals shares fell to $39.62 on Dec. 18 after opening near $42.55, following weeks of sharp gains driven by positive TERN-701 trial data in chronic myeloid leukemia. The company reported a 74% major molecular response rate at 24 weeks in its Phase 1 trial and selected doses for Phase 2 expansion. Trading volume topped 2 million shares.
18 December 2025
··

Stock Market Today

  • Dow, S&P 500, Nasdaq futures dip as financial sector stumbles on private credit risks
    April 11, 2026, 10:02 AM EDT. Dow, S&P 500, and Nasdaq futures edged lower as the financial sector suffered heavy losses, led by insurance stocks. Shares of Ares, Arthur J. Gallagher, Aon, and Willis Towers Watson dropped after a report from rating firm A.M. Best warned of growing risks tied to private credit in insurers' balance sheets. The report highlighted vulnerabilities in annuity products, which now often rely on lower-quality, less transparent issuers, including overseas affiliates. It noted a surge in private equity-backed insurers entering the annuity market, attracted by the spread between premia inflows and crediting rates fueled by private credit returns. Rising concerns about the quality and stability of private credit investments are prompting analysts to flag new financial system risks amid broader economic and geopolitical instability.

Latest article

Wall Street Feels the Heat (and Thrill): Fed Cuts, Tariffs & Mega-Mergers Set NYSE Buzz

US Stock Market Today: Live Updates 11.04.2026

11 April 2026
LIVEMarkets rolling coverageStarted: April 11, 2026, 12:00 AM EDTUpdated: April 11, 2026, 10:08 AM EDT Dow, S&P 500, Nasdaq futures dip as financial sector stumbles on private credit risks April 11, 2026, 10:02 AM EDT. **Dow, S&P 500, and Nasdaq futures** edged lower as the financial sector suffered heavy losses, led by insurance stocks. Shares of **Ares, Arthur J. Gallagher, Aon, and Willis Towers Watson** dropped after a report from rating firm **A.M. Best** warned of growing risks tied to private credit in insurers' balance sheets. The report highlighted vulnerabilities in annuity products, which now often rely on lower-quality, less
UK Stock Market Today: FTSE 100 Climbs as Traders Eye Fragile Iran Ceasefire

UK Stock Market Today: FTSE 100 Climbs as Traders Eye Fragile Iran Ceasefire

10 April 2026
London’s FTSE 100 rose 0.38% to 10,644.28 late Friday morning as investors awaited U.S.-Iran talks in Pakistan. Brent crude climbed 1% to $96.83 a barrel, while sterling eased but was on track for its biggest weekly gain since January. The FTSE 250 gained 0.79%. Britain’s 10-year gilt yield stood at 4.807%.
US Stock Market Today: CPI, Oil and Iran Truce Set the Tone Before the Open

US Stock Market Today: CPI, Oil and Iran Truce Set the Tone Before the Open

10 April 2026
Dow e-minis slipped 0.15% before Friday’s open, with S&P 500 and Nasdaq 100 futures each down 0.08% as traders awaited March CPI data and watched U.S.-Iran tensions. Economists expect headline CPI to rise 0.9% for March and 3.3% year-on-year. Weekly jobless claims increased to 219,000. Brent crude traded near $97 a barrel, while shipping through the Strait of Hormuz remained well below normal.
Wall Street Feels the Heat (and Thrill): Fed Cuts, Tariffs & Mega-Mergers Set NYSE Buzz

US Stock Market Today: Live Updates 10.04.2026

10 April 2026
LIVEMarkets rolling coverageStarted: April 10, 2026, 12:00 AM EDTUpdated: April 10, 2026, 11:59 PM EDT Orora ASX:ORA Faces Earnings Reset After Saverglass Impact and Middle East Disruptions April 10, 2026, 11:59 PM EDT. Orora (ASX:ORA) shares plunged over 8% in one day following a guidance update that revealed an earnings reset at its Saverglass unit due to Middle East supply chain disruptions and a shutdown at the Ras Al Khaimah glass plant. Despite a sharp short-term loss, Orora's 90-day share price rise exceeds 33%, contrasting a longer-term 10.58% annual total shareholder return decline amid ongoing sector pressures. Trading at A$1.49,
Go toTop